Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 3Sarcoma 3Lymphoid 2Gynecologic 2Endocrine 1

Conditions

Sarcoma 3Neoplasm Metastasis 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Carcinoid Tumor 1

Interventions

Radiotherapy 215Cyclophosphamide 210Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Irinotecan 79Magnetic Resonance Spectroscopy 78pembrolizumab 75Radiation 66Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 44Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × conatumumab × Sarcoma × Clear all
NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

Phase 1/2 Terminated
89 enrolled 20 charts
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT00626704 2015-05-25

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Amgen

Phase 1/2 Completed
134 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡